Cancer staging is the process of determining how extensive a cancer is in the body at the time it is diagnosed. It describes features such as the size and local extent of the primary tumour, involvement of nearby lymph nodes, and spread to distant organs. Staging is therefore principally an anatomical description of cancer extent rather than a direct measurement of how abnormal the cancer cells look. It is different from grading, which examines the microscopic characteristics of cancer cells.
Knowing the stage helps clinicians describe the disease consistently, estimate prognosis, select appropriate treatments, assess whether local or systemic treatment is needed, and identify relevant clinical trials. The exact staging rules depend on the cancer type because different cancers behave differently and require different anatomical and biological criteria.
The most widely used general staging framework is the TNM system. T describes the primary tumour, particularly its size and how far it has invaded surrounding structures; N describes whether regional lymph nodes contain cancer and, depending on the cancer, the extent of nodal involvement; and M describes whether distant metastases are present. The precise definitions represented by particular T, N and M numbers or letters vary substantially between cancer types.
For example, a tumour's T category may depend not simply on its diameter but on invasion through particular anatomical layers or into neighbouring structures. N categories may distinguish the number, location or size of affected lymph nodes. M generally distinguishes the absence or presence of distant spread. TNM therefore provides considerably more detail than simply saying that a cancer is stage I, II, III or IV.
TNM information is often combined into an overall stage group. Although the exact grouping differs among cancers, stage 0 generally refers to abnormal cells confined to their original tissue layer, often called carcinoma in situ; stages I, II and III generally represent progressively greater local or regional extent; and stage IV generally indicates distant metastatic disease. The numerical stage should not be interpreted as a universal measurement applicable identically to every cancer.
A stage II cancer of one organ is not necessarily equivalent in biological behaviour, prognosis or treatment to a stage II cancer of another organ. Some cancers use specialised staging systems instead of conventional TNM groupings, including many blood cancers and certain tumours of the brain and spinal cord. Some cancers also incorporate additional biological features into their stage groups, meaning that two tumours with similar anatomical measurements may receive different overall stage classifications.
Staging is established using information gathered from several sources. A biopsy may establish the cancer diagnosis and reveal pathological characteristics, while imaging such as CT, MRI, PET, ultrasound or specialised scans can show the primary tumour, lymph nodes and possible metastases. Blood tests can provide supporting information, although most blood tests cannot by themselves determine the anatomical stage of a solid tumour.
Surgery may provide particularly detailed staging information because lymph nodes and surrounding tissues can be directly examined and sampled. This produces an important distinction between clinical staging and pathological staging. Clinical staging uses information available before definitive surgery, whereas pathological staging incorporates examination of surgically removed tissue. Some cancers also have post-treatment or recurrence-specific staging terminology, and modern systems increasingly incorporate molecular or biomarker information where it has established prognostic or treatment significance.
Staging has several practical purposes beyond describing severity. It helps determine whether surgery is potentially curative, whether radiation should be directed at a local or regional area, whether systemic treatment is appropriate, and whether treatment should be given before or after surgery. Treatment given before definitive local therapy is often called neoadjuvant treatment, whereas treatment after definitive local treatment is commonly called adjuvant treatment.
In metastatic disease, treatment may focus on controlling cancer throughout the body, prolonging survival, maintaining function and relieving symptoms, although some metastatic cancers can still be treated with long-term control or potentially curative strategies in selected circumstances. Staging also permits meaningful comparison of groups of patients in clinical research and helps cancer registries describe disease patterns.
A cancer's stage is generally assigned at diagnosis and does not simply change whenever the disease subsequently progresses. If cancer initially diagnosed as stage II later recurs or metastasises, clinicians describe the recurrence or metastatic progression separately rather than ordinarily replacing the original stage with a new initial stage. This distinction preserves the meaning of survival statistics and treatment outcomes associated with the original diagnosis.
Additional terms such as recurrent, progressive, relapsed, locally advanced or metastatic may describe what happens later. There are exceptions and specialised conventions depending on the cancer registry or clinical context, so terminology in individual medical records can differ. The important conceptual distinction is that initial stage records the extent of disease at a defined point, while subsequent descriptions document how the disease behaves thereafter.
Staging is closely related to prognosis but is not identical to prognosis. Stage provides important information about how far the cancer has spread, but outcome also depends on tumour grade, cancer subtype, molecular alterations, biomarker status, response to treatment, age, general health and other clinical factors. A higher stage generally indicates greater anatomical extent, but stage alone cannot predict exactly what will happen to an individual. Similarly, stage does not necessarily indicate whether a cancer is symptomatic.
A small early cancer can cause major symptoms if it affects a critical structure, while an extensive cancer can sometimes cause relatively few symptoms. Staging should therefore be understood as a structured classification system that supplies essential information for treatment planning and prognosis rather than as a complete description of the patient's disease.
Modern cancer staging continues to evolve because cancer is increasingly understood as a group of biologically diverse diseases rather than solely anatomical masses. Traditional anatomical staging remains fundamental, but pathological subtype, receptor status, genetic alterations and other biomarkers can influence classification and treatment. The practical meaning of a particular stage must therefore be interpreted in the context of the specific cancer type and the staging edition being used.
Terms such as localized, regional and distant may also be used as broader descriptions: localized cancer remains confined to its site of origin, regional cancer has extended to nearby tissues or lymph nodes, and distant cancer has spread to remote sites. The central principle is that staging answers the question of where the cancer is and how extensively it has spread, whereas grading and molecular assessment provide complementary information about what the cancer is biologically like.
